JAZZ
PHARMACEUTICAL PREPARATIONSJazz Pharmaceuticals plc - Ordinary Shares (JAZZ) [ST]
www.jazzpharmaceuticals.com ↗▲ 2.70%
prev close
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Congressional Trades
2
All tracked trades
Members Trading
1
Unique members
Net Activity
+0
1 buys · 1 sells
Members Who Traded This Stock
2 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2023-07-12 | JAZZJazz Pharmaceuticals plc - Ordinary Shares | Sell | $15,001 - $50,000 | 1164d ago | — | |
| 2023-03-06 | JAZZJazz Pharmaceuticals plc - Ordinary Shares | Buy | $15,001 - $50,000 | 1282d ago | — |
2023-07-12
Daniel Goldman
JAZZ
Amount
$15,001 - $50,000
Filed
1164d ago
2023-03-06
Daniel Goldman
JAZZ
Amount
$15,001 - $50,000
Filed
1282d ago
Recent News
Powered by Polygon.io
HRMY Stock Gains 27.6% in Six Months: Is There More Room for Growth?
Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock
Should You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition?
Why Is Jazz (JAZZ) Down 6.9% Since Last Earnings Report?
Axsome Begins Phase III Study on AXS-05 for Smoking Cessation
Trade Timeline
Congressional activity, newest first
Daniel Goldman
2023-07-12 · Sale
$15,001 - $50,000
Daniel Goldman
2023-03-06 · Purchase
$15,001 - $50,000